论文部分内容阅读
目的探讨吉西他滨联合卡铂治疗复发性上皮性卵巢癌的有效性和不良反应。方法对76例复发性上皮性卵巢癌患者应用吉西他滨1 000 mg/m2,第1天和第8天静脉滴注;CBP浓度-时间曲线下面积(AUC)=5,第1天静脉滴注;21天为一个疗程。依据世界卫生组织实体瘤疗效评估标准和国际妇科肿瘤学会卵巢癌疗效判断标准进行疗效评定,并观察化疗后不良反应。结果 76例患者中,完全缓解21例(27.63%),部分缓解36例(47.37%),稳定13例(17.11%),进展6例(7.89%);治疗总有效率75.0%(57/76)。患者无进展生存期平均为4.1个月(2～10个月)。化疗后第8天,中性粒细胞减少、血小板减少、红细胞减少、消化道不良反应的发生率分别84.21%、78.95%、26.32%和86.84%;其他不良反应的发生率均低于20%。无死亡病例。结论吉西他滨联合卡铂是治疗复发性上皮性卵巢癌的有效方案,临床疗效较好,安全性高,其不良反应可控制,患者可耐受。
Objective To investigate the efficacy and adverse reactions of gemcitabine combined with carboplatin in the treatment of recurrent epithelial ovarian cancer. Methods 76 patients with recurrent epithelial ovarian cancer were treated with gemcitabine 1 000 mg / m 2 intravenously on day 1 and day 8; area under the curve of CBP concentration - time (AUC) = 5, intravenous drip on day 1; 21 days for a course of treatment. According to WHO evaluation criteria for the efficacy of solid tumors and the International Gynecologic Oncology Association ovarian cancer curative effect evaluation criteria, and to observe the adverse reactions after chemotherapy. Results Among 76 patients, complete remission was achieved in 21 cases (27.63%), partial remission in 36 cases (47.37%), stable in 13 cases (17.11%) and progression in 6 cases (7.89%). The total effective rate was 75.0% ). Patients with progression-free survival averaged 4.1 months (2 to 10 months). On the 8th day after chemotherapy, the incidences of neutropenia, thrombocytopenia, erythrocyte reduction and gastrointestinal adverse reactions were 84.21%, 78.95%, 26.32% and 86.84%, respectively. The incidence of other adverse reactions was less than 20%. No deaths. Conclusion Gemcitabine combined with carboplatin is an effective regimen for the treatment of recurrent epithelial ovarian cancer. It has good clinical efficacy, high safety and controlled adverse reactions. The patients are tolerant.